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Abstract
On the basis of TP53 mutations and standardized uptake values (SUVs) from 
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought 
to enhance our knowledge of the biology underlying low progesterone receptor 
(PR) expression in estrogen receptor (ER)-positive/human epidermal growth factor 
receptor-2 (HER2)-negative tumors. This study included 272 patients surgically treated 
for ER-positive, HER2-negative breast cancer and who had undergone TP53 gene 
sequencing. Of these, 229 patients also underwent 18F-FDG PET or PET/CT. Mutational 
analysis of exons 5–9 of the TP53 gene was conducted using PCR amplification and direct 
sequencing. The SUVs were measured using 18F-FDG-PET scan images. Twenty-eight 
(10.3%) tumors had a somatic TP53 mutation. The TP53 mutation rate was significantly 
higher in low-PR tumors than in high-PR tumors (17.1% vs 7.9%, P = 0.039). Low-PR tumors 
had significantly higher median SUVs than high-PR tumors (P = 0.046). The multivariable 
analysis revealed that SUV and age remained independent variables associated with low 
PR expression. An adverse impact of low PR expression on recurrence-free survival was 
observed in the multivariable Cox regression hazard model. We provide clinical evidence 
that genetic alteration of the TP53 gene and dysregulated glucose metabolism partly 
involve low PR expression in ER-positive and HER2-negative breast cancer.
Background
In estrogen receptor (ER)-positive breast cancer, 
progesterone receptor (PR) expression is generally 
considered a marker of an intact estrogen-responsive 
pathway (Horwitz & McGuire 1975). In addition, patients 
with ER-positive/PR-negative breast cancers have a worse 
prognosis than that of patients with PR-positive tumors 
(Clark  et  al. 1983). Recently, two studies suggested that 
low or negative PR expression can be used to identify 
‘luminal B-like’ cancer, which has a poor outcome and is 
distinguished from ‘luminal A-like’ cancer in ER-positive/
human epidermal growth factor receptor-2 (HER2)-
negative cancer (Cancello et al. 2013, Prat et al. 2013).
Therefore, many investigators have tried to dissect 
tumor biology regarding the loss of PR in ER-positive 
cancer. Previous studies using human tumor samples 
suggested several lines of evidence that a higher rate 
of TP53 mutation (Olivier  et  al. 2006), DNA copy-
number gain or increasing PI3K/mTOR gene signature 
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(Creighton et al. 2009), and activation of the growth factor 
signal pathway (Arpino  et  al. 2005) could be associated 
with loss of PR expression in ER-positive cancer. However, 
these studies included both ER-positive/HER2-positive and 
-negative tumors; thus, previous findings on the loss of 
PR expression might be affected by HER2 overexpression. 
Molecular studies based on next-generation sequencing 
showed that HER2-enriched tumors more frequently 
harbor TP53 mutation than luminal A or luminal B tumors 
(Desmedt et al. 2012, Bertheau et al. 2013). Furthermore, 
standard of care for ER-positive/HER2-positive patients 
is anti-HER2 therapy plus chemotherapy followed by 
endocrine therapy, differing from that for ER-positive/
HER2-negative patients (Goldhirsch et al. 2013).
Our group previously reported the prognostic 
influence of the standardized uptake value (SUV) on 
18F-fluorodeoxyglucose positron emission tomography 
(18F-FDG-PET), which represents glucose uptake, in 
ER-positive breast cancer (Ahn et al. 2014a,b). In addition, 
we found a positive correlation between the SUV and 
the 21-gene recurrence score (RS) in ER-positive/HER2-
negative disease (Ahn et al. 2017).
In this study, we first questioned whether the rate of 
TP53 mutation was higher in low-PR tumors than that 
in high-PR tumors among ER-positive/HER2-negative 
breast cancer. Second, we compared SUVs according to 
PR status in these tumors. This study sought to enhance 
our understanding of the biology underlying low PR 
expression within ER-positive/HER2-negative tumors.
Patients and methods
Patients
This study included 272 patients surgically treated for 
ER-positive, HER2-negative breast cancer and who had 
undergone TP53 gene sequencing between March 2007 
and December 2015 at Gangnam Severance Hospital, 
Yonsei University College of Medicine. Patients who were 
treated with neoadjuvant chemotherapy and those who 
were diagnosed with recurrent or metachronous breast 
cancer were excluded from this study. Patients with ductal 
carcinoma in situ were also excluded. Of the 272 patients, 
229 also underwent 18F-FDG PET or PET/computed 
tomography (CT) as part of routine preoperative staging.
The staging was performed according to the 7th 
edition of the American Joint Committee on Cancer system 
(Edge & Compton 2010). The Elston-Ellis modification 
of the Scarff-Bloom-Richardson grading system was 
used for histologic grading. Adjuvant systemic therapy 
and/or radiotherapy were administered according to the 
standard guidelines based on patient age, primary tumor 
characteristics and axillary lymph node status. Endocrine 
therapy was administered to all patients. The follow-up 
protocol included planned regular visits every 6 months; 
missed appointments were followed-up by telephone calls 
to minimize the number of patients lost to follow-up and 
to improve the accuracy of the survival data. The final 
update to the clinical database was made in March 2018. 
Our study was approved by the Institutional Review 
Board of Gangnam Severance Hospital, Yonsei University, 
Seoul, Korea, in accordance with the good clinical practice 
guidelines under the Declaration of Helsinki.
Definition of low PR expression and 
immunohistochemical (IHC) study
We defined low PR expression based on the modified 
Allred system (Harvey  et  al. 1999): low, Allred score 
0–4; and high, Allred score 5–8. ER expression was also 
evaluated in the same manner. All tumors included in 
this study were ER positive (Allred scores ≥3). HER2 status 
was evaluated according to the 2013. American Society 
of Clinical Oncology/College of American Pathologists 
(ASCO-CAP) guidelines (Wolff  et  al. 2013) and was 
negative for all cases. The antibodies used for the IHC 
study were described previously. Ki67 expression was 
measured by an experienced pathologist and reported as 
a percentage score (range 0–100%) of positive tumor cells.
TP53 Sanger sequencing
Mutational analysis of exons 5–9 of the TP53 gene was 
conducted using PCR amplification and direct sequencing 
(Kim  et  al. 2014). The primers designed to amplify the 
exons and flanking introns of the TP53 gene were described 
previously (Kim et al. 2014). Briefly, PCR was performed 
using an Accu-PowerTM Premix (Bioneer, Daejeon, Korea) 
under the following amplification conditions: 94°C for 
4 min followed by 50 cycles of 94°C for 1 min, 60°C for 
30 s and 72°C for 30 s and final extension at 72°C for 
15 min. Purified PCR products obtained using a QIAquick 
Gel Extraction kit (Qiagen) were used for sequencing with 
a Big Dye Terminator Cycle Sequencing Ready Reaction 
kit (Applied Biosystems). The thermal cycler conditions 
were as follows: 96°C for 5 min followed by 24 cycles of 
96°C for 10 s, 50°C for 5 s and 60°C for 4 min and final 
extension at 72°C for 5 min. The sequences were analyzed 
using an ABI 3500Dx system (Applied Biosystems). The 
TP53 sequences were compared to the GenBank database 
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sequence (accession number NC_000017.9) (Cancer 
Genome Atlas Network 2012). Both forward and reverse 
strands were sequenced to confirm the full sequence 
length (bp) and nucleotide alterations (Kim et al. 2013).
18F-FDG PET or PET/CT method
The procedure for 18F-FDG PET or PET/CT was as 
previously reported (Ahn et al. 2014b, Lee et al. 2016). The 
SUV was calculated by measuring the 18F-FDG uptake by 
the primary tumor in the region of interest, as follows: 
SUV = (maximal radioactivity concentration in the region 
of interest)/(injected dose/patient’s weight (kg)).
Statistical analysis
Continuous variables were compared using Mann–
Whitney U test. Discrete variables were compared using 
χ2 or Fisher’s exact tests. The SUV was incorporated into 
the analyses as a continuous variable. Kolmogorov–
Smirnov tests were used to assess the normal distribution 
of the SUV. To identify predictive factors for low PR 
expression, the binary logistic regression analysis was 
performed using all variables. The variables with P value 
<0.05 were included in the full multivariable model, and 
the stepwise backward Wald method was used to arrive at 
the final model. No adjustments were made for multiple 
statistical testing.
The recurrence-free survival time (RFS) was measured 
from the date of the first curative surgery to the date 
of the first tumor recurrence, including loco-regional 
recurrence, distant metastasis or death. The Kaplan–Meier 
method was used to estimate the RFS, and the estimated 
survival curves were compared using the log-rank test. The 
Cox’s regression-hazard model was used for univariable 
and multivariable survival analyses. Significant variables 
in univariable analysis are included in the multivariable 
model. Variables that were significant at the 0.05 level 
were then selected to build a predictive multivariable 
Cox regression survival model. A backwards selection 
method (P = .05 for inclusion and P = .05 for exclusion, 
wald method) was used to identify significant prognostic 
factors for the RFS. In addition, a predictive ability of 
multivariable was measured using Harrell c-statistics 
(Harrell et al. 1996) and the concordance index (c-index) 
was calculated to measure the concordance for time-to-
event data, in which increasing values between 0.5 and 
1.0 indicated improved prediction. PASW Statistics for 
Windows, version 18.0 (SPSS, Inc.) and the R software 
(version R-3.3.3; https://www.r-project.org) were used to 
perform these analyses. Statistical significance was defined 
as P values <0.05 or 95% CIs.
Results
Baseline characteristics
Two hundred seventy-two patients with ER-positive, 
HER2-negative tumors were included in the analyses. 
Two hundred two (74.3%) and seventy (25.7%) patients 
had a high and low PR expression, respectively, while 
241 (88.6%) and 31 (11.4%) patients had high and low 
ER expression, respectively. The baseline characteristics 
were compared according to PR expression (Table 1). The 
median age of the low PR group was significantly younger 
than that of the high PR group (P < 0.001). There were 
no differences in anatomical staging, whereas histologic 
grade tended to be higher in low-PR tumors (P = 0.064). 
Also, the proportion of tumors with ER expression differed 
significantly according to PR expression (P = 0.019), while 
the proportion of tumors with high Ki67 expression did 
not differ by PR expression.
Table 1 Baseline characteristics.
High PR (N = 202) Low PR (N = 70) P-Valuea
Median age, 
years (range)
57 (31–91) 49 (26–81) <0.001b
T stage 0.139
 T1 113 (55.9) 32 (45.7)
 T2 89 (44.1) 38 (54.3)
N stage 0.194c
 N0 124 (61.4) 51 (72.9)
 N1 66 (32.7) 14 (20.0)
 N2 8 (4.0) 4 (5.7)
 N3 4 (2.0) 1 (1.4)
Stage 0.751
 I 79 (39.1) 24 (34.3)
 II 108 (53.5) 41 (58.6)




 I 60 (30.3) 15 (22.4)
 II 109 (55.1) 34 (50.7)




 High 184 (91.1) 57 (81.4)
 Low 18 (8.9) 13 (18.6)
Ki67 0.980
 ≥20% 43 (21.3) 15 (21.4)
 <20% 159 (78.7) 55 (78.6)
aChi-square test except; bMann–Whitney U test; cFisher exact test; 
dmissing values; ehigh, Allred score 5–8; low, Allred score 0–4.
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High TP53 mutation rates in low-PR tumors
Tumors from 28 patients (10.3%) had a somatic TP53 
mutation. The diverse locations of mutations within the 
TP53 coding sequence are shown in Supplementary data 1 
(see section on supplementary data given at the end of this 
article). Among six ‘hotspot’ residues (R175, G245, R248, 
R249, R273 and R282) (Cho et al. 1994), our patients had two 
R248 and two R273 missense mutations. Missense mutations 
were most common (19 of 28; 67.9%), followed non-sense 
mutations (4 of 28), splicing mutations (3 of 28) and frame-
shift mutations (2 of 28) (Supplementary data 1). The TP53 
mutation rate was significantly higher in low-PR tumors 
than that in high-PR tumors (17.1% vs 7.9%, P = 0.039; 
Fig.  1A). However, the TP53 mutation rate was not statis-
tically different according to ER expression (6.5% in low-ER-
tumors vs 10.8% in high-ER tumors, P = 0.752; Fig. 1B).
SUV in relation to PR expression
To investigate the pathologic characteristics of tumors 
in terms of glucose uptake, we measured SUV in patients 
undergoing preoperative 18f-FDG-PET. We obtained 
SUVs from 229 patients (84.2%). We compared the SUV 
distributions according to PR expression because the SUVs 
were not normally distributed (P < 0.001, Kolmogorov–
Smirnov test). The SUV distributions differed significantly 
according to PR expression (P = 0.046, Mann–Whitney U 
test), indicating that low-PR tumors had a significantly 
higher median SUV than that of high-PR tumors (Fig. 2A). 
However, the median SUVs were not statistically different 
according to ER expression (P = 0.835, Fig. 2B).
SUV is predictive of low PR expression
We identified the factors associated with low-PR expression 
using binary logistic regression analysis. The variables 
with P < 0.05 in univariate analysis included age, TP53 
mutation, tumor grade and SUV (Table 2). Multivariable 
analysis revealed that SUV and age remained independent 
variables associated with low PR expression (Table  2). 
Continuous SUV had an odds ratio (OR = 1.220; 95% 
confidence interval (CI) = 1.068–1.394) for predicting 
low-PR tumors in multivariable analysis.
Survival analysis
At a median follow-up of 50 months (3–134), 18 patients 
experienced tumor recurrence, including 17 distant 
metastases and one loco-regional recurrence. Among the 
18 patients with recurrence, three had both metastases and 
loco-regional recurrences. During the follow-up period, 
one patient died from breast cancer, and one patient died 
from a non-cancerous cause. The adjuvant treatments, 
presented online, were not statistically different according 
to PR expression (Supplementary data 2).
The Kaplan–Meier plots for RFS differed significantly 
according to PR expression (P = 0.016; Fig.  3A). The 
RFS was longer in the groups with high-PR tumors; 
however, a significant difference of the RFS according 
to the presence of TP53 mutation was not observed 
(P = 0.911; Fig. 3B).
In the univariable analyses using the Cox regression 
model, T stage, N stage, stage, SUV and PR expression were 
significant (Table  3). In the multivariable model, stage 
and PR expression were significant prognostic factors for 
the RFS (Table 3). Then, we compared a predictive ability 
of the multivariable model with or without SUV using the 
Harrell c-statistics. For the model 1 (without SUV), the 
Harrell c-index was 0.713. For the model 2 (with SUV), 
the Harrell c-index was 0.687, indicating that SUV does 
not add a predictive power to the model 1 that includes 
stage and PR expression.
Figure 1
TP53 mutation rates according to PR and ER 
status. (A) The TP53 mutation rate was 
significantly higher in low-PR tumors than that in 
high-PR tumors (17.1% vs 7.9%, P = 0.039). (B) The 
rates were not statistically different according to 
ER expression (10.8% in high-ER tumors vs 6.5% in 
low ER-tumors, P = 0.752).
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In this study, tumors with low PR expression more 
frequently had TP53 mutations and elevated glucose 
uptake compared to those in tumors with high PR 
expression, providing a biological rationale for why low PR 
expression could be a biomarker to distinguish aggressive 
tumors from ER-positive/HER2-negative tumors, similar 
to high Ki67 level or poor histologic grade. Our findings 
are in line with those of previous studies indicating that 
the loss of PR expression correlates with aggressive tumor 
characteristics (Arpino et al. 2005, Olivier et al. 2006) and 
with a gene signature of the PI3K/Akt/mTOR pathway 
(Creighton et al. 2009).
An earlier study of 1794 breast cancer patients showed 
that TP53 mutations were more frequent in PR-negative 
tumors than those in PR-positive tumors (Olivier et  al. 
2006) but did not identify HER2 status, remaining unclear 
Figure 2
Distribution of SUVs according to PR and ER 
status. (A) Low-PR tumors had a significantly 
higher median SUV than that of high-PR tumors 
(P = 0.046, Mann–Whitney U test). The median 
SUVs for low- and high-PR tumors were 4 
(1.4–12.2) and 3.3 (0.91–14), respectively. (B) The 
median SUVs were not statistically different 
according to ER expression (P = 0.835, Mann–
Whitney U test). The median SUVs for low- and 
high-ER tumors were 3.7 (1.4–10.5) and 3.4 
(0.91–14.0), respectively.
Table 2 Binary logistic regression analysis to identify predictive factors for low PR expression.
Variables
Univariable Multivariable
P-Value OR (95% CI) P-Value OR (95% CI)
Age (per 1 year) 0.001 1.044 (1.018–1.071) 0.003 1.043 (1.014–1.073)
TP53 mutation 0.033 2.405 (1.076–5.377)
Grade
 I Ref
 II 0.526 1.248 (0.629–2.474)
 III 0.029 2.483 (1.098–5.615)
SUV (per 1 unit) 0.003 1.218 (1.070–1.387) 0.003 1.220 (1.068–1.394)
T stage
 T1 Ref
 T2 0.141 1.508 (0.873–2.603)
N stage
 N0 Ref
 N1 0.050 0.516 (0.266–1.000)
 N2 0.758 1.216 (0.350–4.217)
 N3 0.660 0.608 (0.066–5.571)
Stage
 I Ref
 II 0.453 1.250 (0.699–2.235)
 III 0.870 1.097 (0.361–3.331)
ER expressiona
 High Ref
 Low 0.021 2.351 (1.135–4.868)
Ki67
 ≥20% Ref
 <20% 0.98 0.992 (0.511–1.924)
aHigh, Allred score 5–8; low, Allred score 0–4.
ER, estrogen receptor; SUV, standardized uptake.
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whether the TP53 mutation rate is higher in PR-lacking 
tumors within ER-positive/HER2-negative tumors. 
We observed that the rate was significantly higher in 
low-PR tumors within luminal/HER2-negative tumors, 
suggesting that frequent TP53 pathway defects could 
characterize ER-positive/PR-low tumors even without 
HER2 amplification.
A comprehensive genomic study using whole genome 
analyses showed that TP53 mutations contribute to 
endocrine failure in luminal breast cancer (Ellis  et  al. 
2012). A bioinformatics analysis integrating gene copy 
number aberrations, gene expression profiles and 
mutations indicated that TP53 mutations play an integral 
role in determining luminal B status and resistance to 
endocrine therapy (Ellis et al. 2012). Furthermore, ~30% 
of luminal B tumors harbored TP53 mutant in TCGA 
data (Cancer Genome Atlas Network 2012), suggesting 
that a considerable number of luminal B tumors have 
an impaired TP53 pathway. Our observations of TP53 
mutations and low PR expression consolidate a current 
consensus that low PR expression can be used to identify 
luminal B-like tumors (Goldhirsch et al. 2013, Coates et al. 
2015) and provide a rationale that low-PR tumors have a 
worse prognosis than high-PR tumors even though they 
are all ER-positive/HER2-negative tumors.
In addition to TP53 mutations, we also characterized 
the low-PR tumors using the SUV as an objective numerical 
value indicative of glucose uptake within tumors. Based 
on a study elucidating the tumor biology of increasing 
SUV such as MYC-overexpression (Palaskas et al. 2011) or 
centromere protein F-expression, breast cancer with high 
SUV levels could indicate aggressive tumors. Moreover, 
our previous study showed that high SUV could be a 
poor prognostic factor in luminal breast cancer, also 
concordant with another study (Aogi et al. 2015), which 
similarly evaluated the prognosis of luminal breast cancer 
according to SUV. In another study of luminal/HER2-
negative tumors, we found that SUV is correlated with the 
21-gene recurrence score and inversely correlated with PR 
mRNA expression (Ahn et al. 2017). Our previous finding 
on the inverse correlation between SUV and PR mRNA 
expression is concordant with the findings of this study 
that low-PR tumors had a higher SUV. Several lines of 
evidence suggest that growth factor signaling is frequently 
activated in PR-lacking tumors (Cui et al. 2005), supporting 
our findings that enhanced growth factor pathway 
expression may contribute to increased glycolysis (Vander 
Heiden  et  al. 2009). Further studies on the relationship 
between the loss of PR and increased glycolytic activity in 
this subset of breast cancer are warranted.
Our major limitation is the potential argument against 
the optimal PR expression threshold. Although Prat et al. 
suggested a cut-off of 20% (Prat et al. 2013) based on the 
relationship between mRNA levels of the PR gene and 
IHC examination, it is still hard to clearly distinguish low 
and high PR tumors using IHC examination alone. Expert 
panels largely agreed that low PR expression can be utilized 
as a determinant for luminal B-like tumors (Goldhirsch 
et  al. 2013, Coates et  al. 2015), but recommended its 
combination with other pathologic markers such as Ki67 
and grade (Coates et al. 2015). More research is needed to 
determine the optimal PR expression cut-off.
Another limitation is noted in the survival analyses. 
In multivariable model 1, the poor prognostic impact 
of low PR expression was observed but disappeared in 
multivariable model 2. Also, the negative impact of high 
SUV on survival suggested by previous studies was not 
found in model 2. This might be due to the small number of 
recurrences and missing SUV data. Much longer follow-up 
is required to identify the influence of PR status and SUV 
in those patients because luminal/HER2-negative patients 
generally have a very favorable outcome. In addition, 
a method of selective hot-spot sequencing could be 
regarded as a limitation because it does not discover any 
kinds of genetic change of whole exome. Also, high SUV 
in low PR-tumors cannot be excluded as a mere reflection 
of poorly differentiated carcinoma because low-PR tumors 
tend to have high histologic grade.
Figure 3
Kaplan–Meier plots of recurrence-free survival 
(RFS). (A) The RFS differed significantly according 
to PR expression (P = 0.016, log-rank test). (B) 
However, the RFS did not differ significantly 
according to the presence of TP53 mutation 
(P = 0.911, log-rank test).
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Despite these limitations, our study characterized 
low-PR tumors in terms of altered TP53 pathway and 
glucose metabolism. It is worth exploring low-PR tumors 
in viewpoints of these biologic pathways. Moreover, 
these characteristics of low-PR tumors partly explain why 
low-PR tumors have a worse outcome among luminal/
HER2-negative breast cancer that generally shows a 
favorable course.
Conclusions
We provide evidence that genetic alteration of the TP53 
gene and dysregulated glucose metabolism partly involve 
low PR expression in ER-positive and HER2-negative 
breast cancer.
Supplementary data
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Table 3 A cox-regression hazard model for recurrence-free survival.
Variables
Univariable Multivariable
P-Value HR (95% CI)
Model 1 (backward) Model 2 (backward + SUV)
P-Value HR (95% CI) P-Value HR (95% CI)
Age 0.740 1.008 (0.963–1.054)
TTP53 mutation 0.912 0.891 (0.116–6.848)
SUV 0.046 1.231 (1.004–1.509) 0.577 1.071 (0.842–1.362)
Grade
 I 0.482 Ref
 II 0.381 1.528 (0.468–4.987)
 III 0.046 1.970 (0.432–8.985)
T stage
 T1 Ref
 T2 0.004 5.235 (1.674–16.372)
N stage
 N0 Ref
 N1 0.376 0.562 (0.157–2.010)
 N2 0.700 1.497 (0.192–11.709)
 N3 0.000 18.300 (3.873–86.470)
Stage
 I Ref Ref Ref
 II 0.080 3.190 (0.872–11.661) 0.079 3.208 (0.872–11.795) 0.245 2.237 (0.576–8.684)
 III 0.007 8.031 (1.791–36.015) 0.007 7.980 (1.776–35.852) 0.061 7.164 (0.911–56.332)
ER expression
 High Ref
 Low 0.473 0.580 (0.131–2.572)
Ki67
 ≥20% Ref
 <20% 0.175 0.506 (0.189–1.355)
PR expression 0.024 0.067
 High Ref Ref Ref
 Low 0.023 2.955 (1.165–7.499) 2.953 (1.152–7.567) 2.793 (0.932–8.367)
Harrell c-index 0.718 0.687
ER, estrogen receptor; PR, progesterone receptor; SUV, standardized uptake value.
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and adhered to the tenets of the Declaration of Helsinki. Owing to the 
retrospective approach of this study, the need for informed consent was 
waived by the ethics committees.
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